Skip to main content
MarketStoryBook
All storiesAMGN in “GLP-1 Eats Everything”AMGN in storiesAMGN stock

AMGN in “GLP-1 Eats Everything”

Amgen Inc.

Bull sideFadingExposure: not rated yet

MariTide gives Amgen a differentiated, long-acting obesity candidate that could capture meaningful share of the expanding GLP-1 market.

AMGN impact map — “GLP-1 Eats Everything”

How this story travels from the headline to AMGN’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading AMGN impact map…

Price history, marked with story events

Oct 15, 2025 – Oct 16, 2026 · 254 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

GLP-1 Eats Everything

Appetite suppression as a macro variable.

BULL side — MariTide gives Amgen a differentiated, long-acting obesity candidate that could capture meaningful share of the expanding GLP-1 market.

Read the full GLP-1 Eats Everything story

Bull side

1 story

  • AMGN in “GLP-1 Eats Everything”

    FadingExposure: not rated yet
    Viewing

    Appetite suppression as a macro variable.

    MariTide gives Amgen a differentiated, long-acting obesity candidate that could capture meaningful share of the expanding GLP-1 market.

Bear side

2 stories
  • America Imports the World's Drug Prices

    AMGN in “America Imports the World's Drug Prices”

    StableExposure: not rated yet

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Although Amgen sells biosimilars, its larger innovative-biologics franchise leaves it a net loser from lower benchmarked prices and reduced blockbuster value.

  • The Patent Cliff Sparks a Biotech Land Grab

    AMGN in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    Amgen faces mature-product pressure and carries greater balance-sheet constraints after using a large acquisition to replenish growth.